Companies · Biotechnology

Armonica Technologies, Inc.

ALBUQUERQUE · Biotechnology

Diligence memoA one-page analyst read on Armonica Technologies, Inc. — recommendation, valuation, rhythm, risks.
$7.0M
Total raised · real
3
Rounds
2.0×
Latest step-up
Top 51%
Sector rank · raised
Series A
Latest stage · inferred · Thu Nov 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Armonica Technologies, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.72× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
  • Within the normal band (72% of peer median) for its niche.
Active
  • Last raise 7 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Armonica Technologies, Inc. is one of 4293 Biotechnology companies tracked from ALBUQUERQUE. By capital raised it ranks mid-pack (ahead of 50% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
8
Investors (latest)
2025-11-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MPre-Seed · 2017-08-08 Raised $765K (real) Modeled valuation $42M (est)$765K$42MPre-Seed2017Seed · 2021-10-06 Raised $2.1M (real) Modeled valuation $46M (est)$2.1M$46MSeed2021Series A · 2025-11-20 Raised $4.2M (real) Modeled valuation $11M (est)$4.2M$11MSeries A2025+$2.1M+$4.2MCumulative $7.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$765K · 2017
Seed$2.1M · 2021
Series A$4.2M · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$11.3M
Base estimate est.
$4.6M
Conservative case
$17.8M
Upside case
$19.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $42.2M · 2017-08-082017Seed · modeled $45.7M · 2021-10-06Series A · modeled $11.3M · 2025-11-202025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
50 mo
Avg between rounds
$851K/yr
Capital velocity
8.9 yr
On record since
2017
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× of median
This company$7.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.8× of median
This company$4.2M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.2× of median
This company$11.3M
Sector median$64.2M

Raised more than 50% of sector peers (real $). Modeled value above 20% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #111 of 157.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Acasti Pharma Inc. · Series A Raised $23.0M · modeled $58.6M (est)Edesa Biotech, Inc. · Series A Raised $36.9M · modeled $58.5M (est)4DMedical Ltd · Series A Raised $15.0M · modeled $50.7M (est)Arialys Therapeutics, Inc. · Series A Raised $29.1M · modeled $49.2M (est)Nuclein, LLC · Series A Raised $34.5M · modeled $48.3M (est)Phantom Neuro Inc. · Series A Raised $15.4M · modeled $45.7M (est)Circulate Health, Inc. · Series A Raised $13.0M · modeled $43.3M (est)Biovantix Biotechnology, Inc · Series A Raised $15.0M · modeled $42.2M (est)Bariendo Inc. · Series A Raised $11.1M · modeled $40.9M (est)ENDRA Life Sciences Inc. · Series A Raised $26.8M · modeled $40.9M (est)Medici Therapeutics, Inc. · Series A Raised $14.8M · modeled $39.8M (est)Onconetix, Inc. · Series A Raised $22.0M · modeled $37.7M (est)Armonica Technologies, Inc. (this company) Raised $7.0M · modeled $11.3M (est)Armonica Technologies, Inc.
CompanyStageRaised · realValue · estvs peer med.
Acasti Pharma Inc.Series A$23.0M$58.6M3.75×
Edesa Biotech, Inc.Series A$36.9M$58.5M3.74×
4DMedical LtdSeries A$15.0M$50.7M3.24×
Arialys Therapeutics, Inc.Series A$29.1M$49.2M3.14×
Nuclein, LLCSeries A$34.5M$48.3M3.09×
Phantom Neuro Inc.Series A$15.4M$45.7M2.92×
Circulate Health, Inc.Series A$13.0M$43.3M2.77×
Biovantix Biotechnology, IncSeries A$15.0M$42.2M2.70×
Bariendo Inc.Series A$11.1M$40.9M2.61×
ENDRA Life Sciences Inc.Series A$26.8M$40.9M2.61×
Medici Therapeutics, Inc.Series A$14.8M$39.8M2.54×
Onconetix, Inc.Series A$22.0M$37.7M2.41×
Armonica Technologies, Inc. this companySeries A$7.0M$11.3M0.72×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$765K2017-08-08$4.2M$42.2M90%
Seed$2.1M2021-10-06$10.4M$45.7M90%
Series A$4.2M2025-11-20$19.2M$11.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$765K2017-08-08
    • First recorded raise — entered as Pre-Seed.
    • 5 investors on this round.
  2. Seed$2.1M2021-10-06
    • Raised again after 50 mo — slower than the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
    • 4 investors on this round.
  3. Series A$4.2M2025-11-20
    • Raised again after 49 mo — slower than the ~14 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 8 investors on this round.
Intelligence
2030 ~Q1
Modeled next raise · ~50mo cadence
$8.6M
Modeled next size est.range $5.6M$13.7M
2.0×
Last step-up
$851K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Blivin13 other2021-10
Waneta Tuttle5 other2021-10
Sally Corning4 other2021-10
Waneta C. Tuttle3 other2017-08
Brian C Birk1 other2017-08
David C Blivin1 other2017-08
Steven R.J. Brueck1 other2017-08
Todd Dickinson1 other2025-11
Victor Esch1 other2021-10
Emily Milsovic2025-11
Scott Goldman2021-10
Scott L. Goldman2017-08
Stephen Brueck2021-10
Zachary R.J. Lerner2017-08
Registry & provenance

Armonica Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1714729
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Nanomr, Inc.BiotechnologySeries A$18.5M$86.8Mnetwork3 shared operators · same sector · same stage
BennuBio, Inc.BiotechnologySeries A$6.8M$21.4Mnetwork2 shared operators · same sector · same stage
AgilVax, Inc.BiotechnologySeed$4.2M$133.2Mnetwork3 shared operators · same sector
Circular Genomics Inc.BiotechnologySeries A$12.6M$54.7Mnetwork2 shared operators · same sector · same stage
WaveFront Dynamics Inc.BiotechnologySeries A$8.4M$39.7Mnetwork1 shared operator · same sector · same stage
Exagen Diagnostics IncBiotechnologySeries B$88.5M$261.4Mnetwork2 shared operators · same sector
BayoTech, Inc.AgricultureSeries A$16.4M$11.9Mnetwork2 shared operators · same stage
EtiraRX, Inc.BiotechnologySeries A$7.2M$8.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ARMR Sciences Inc.BiotechnologySeries B$130.1M90%
ArmaGen, Inc.BiotechnologySeries A$361.5M90%
Senseonics Holdings, Inc.BiotechnologySeries B$98.9M88%
Akonni Biosystems IncBiotechnologySeries A$64.2M87%
Artelo Biosciences, Inc.BiotechnologySeries A$723K87%
Axion BioSystems, Inc.BiotechnologySeries A$289.2M86%
Pana Bio, Inc.BiotechnologyPre-Seed$4.9M86%
Axim Biotechnologies, Inc.BiotechnologyPre-Seed$27.6M85%
Frequently asked
How much funding has Armonica Technologies, Inc. raised?
Armonica Technologies, Inc. has raised approximately $7.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Armonica Technologies, Inc.'s estimated valuation?
Provath's modeled valuation for Armonica Technologies, Inc. is approximately $11.3M (modeled range $4.6M–$17.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Armonica Technologies, Inc. at?
Armonica Technologies, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Thu Nov 20.
What does Armonica Technologies, Inc. do and where is it based?
Armonica Technologies, Inc. operates in the Biotechnology sector, based in ALBUQUERQUE.
Explore related

See where Armonica Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Armonica Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.